thymoquinone has been researched along with Prostatic Neoplasms in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Alemi, F; Asemi, Z; Fazlollahpour Naghibi, A; Karimian, A; Majidinia, M; Moliani, A; Yousefi, B | 1 |
| Chen, H; Cheng, J; Du, J; Fu, J; Fu, S; Guo, K; He, J; He, T; Li, D; Li, T; Liu, S; Liu, X; Liu, Z; Qian, J; Song, B; Tan, Q; Zhang, L; Zhou, B | 1 |
| Arvizu-Espinosa, MG; Estrada-Meza, C; Osorio-Pérez, SM; Paul, S; Ruiz-Manriquez, LM; Sharma, A; Srivastava, A | 1 |
| Kohno, S; Kumar, S; Linn, P; Nagatani, N; Soga, T; Takahashi, C; Watanabe, Y | 1 |
| A Dera, A; Al Fayi, M; Alshyarba, M; Otifi, H; Rajagopalan, P | 1 |
| Duan, P; Guo, F; Kou, B; Kou, Q; Li, J; Liu, W; Yang, Y; Yi, Q; Zhao, W; Zhou, J | 1 |
| Atmaca, H; Bozkurt, E; Dirican, A; Erten, C; Karaca, B; Uslu, R | 1 |
| Abdel-Mageed, AB; Agrawal, KC; Koka, PS; Mondal, D; Schultz, M | 1 |
| Benghuzzi, H; Hughes, J; Jones, P; Richards, LR; Tucci, M | 2 |
| Chen, D; Chinnakannu, K; Dou, QP; Kaseb, AO; Menon, M; Reddy, GP; Sivanandam, A; Tejwani, S | 1 |
11 other study(ies) available for thymoquinone and Prostatic Neoplasms
| Article | Year |
|---|---|
The modulatory effects of two bioflavonoids, quercetin and thymoquinone on the expression levels of DNA damage and repair genes in human breast, lung and prostate cancer cell lines.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Apoptosis; Cell Line, Tumor; DNA Damage; Flavonoids; Humans; Lung; Male; MCF-7 Cells; Prostatic Neoplasms; Quercetin; Tumor Suppressor Protein p53; X-ray Repair Cross Complementing Protein 1 | 2022 |
Impact of
Topics: Adenosine; COVID-19; COVID-19 Drug Treatment; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Prostatic Neoplasms; SARS-CoV-2; Serine Endopeptidases | 2022 |
Thymoquinone Potentially Modulates the Expression of Key Onco- and Tumor Suppressor miRNAs in Prostate and Colon Cancer Cell Lines: Insights from PC3 and HCT-15 Cells.
Topics: Cell Line, Tumor; Colonic Neoplasms; Humans; Male; MicroRNAs; PC-3 Cells; Prostate; Prostatic Neoplasms | 2023 |
Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion.
Topics: Animals; Apoptosis; Benzoquinones; Cell Line, Tumor; Gene Deletion; HEK293 Cells; Humans; Male; Mice, Knockout; Mice, Nude; Mice, SCID; PC-3 Cells; Prostatic Neoplasms; Retinoblastoma Protein; Succinate-CoA Ligases; Tetradecanoylphorbol Acetate | 2020 |
Thymoquinone inhibits IL-7-induced tumor progression and metastatic invasion in prostate cancer cells by attenuating matrix metalloproteinase activity and Akt/NF-κB signaling.
Topics: Antineoplastic Agents, Phytogenic; Benzoquinones; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Interleukin-7; Male; Matrix Metalloproteinase 3; Matrix Metalloproteinase 7; NF-kappa B; Nigella sativa; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Tumor Cells, Cultured | 2021 |
Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway.
Topics: Benzoquinones; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta | 2017 |
Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Blotting, Western; Cell Proliferation; Docetaxel; Drug Synergism; Humans; Male; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Taxoids; Tumor Cells, Cultured | 2015 |
Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species.
Topics: Antineoplastic Agents; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Profiling; Humans; Inhibitory Concentration 50; Male; Nigella sativa; Prostatic Neoplasms; Reactive Oxygen Species; Signal Transduction | 2010 |
The physiological effect of conventional treatment with epigallocatechin-3-gallate, thymoquinone, and tannic acid on the LNCaP cell line.
Topics: Antineoplastic Agents; Antioxidants; Benzoquinones; Catechin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Humans; Male; Prostatic Neoplasms; Tannins; Treatment Outcome | 2006 |
LNCaP cells exposed to ceramic drug delivery treatment with epigallocatechin-3-gallate, thymoquinone, and tannic acid.
Topics: Anticarcinogenic Agents; Antioxidants; Benzoquinones; Catechin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Ceramics; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Humans; Male; Neoplasm Proteins; Prostatic Neoplasms; Tannins | 2007 |
Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer.
Topics: Androgen Receptor Antagonists; Animals; Benzoquinones; Cell Growth Processes; Cell Line, Tumor; E2F1 Transcription Factor; G1 Phase; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; S Phase; Xenograft Model Antitumor Assays | 2007 |